Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Practice Patterns and Incidence of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients: Multicenter Survey of Transplant Centers in the United States.

Papanicolaou GA, Dvorak CC, Dadwal S, Maron G, Prasad VK, Giller R, Abdel-Azim H, Sadanand A, Casciano R, Chandak A, Huang S, Nichols G, Brundage T, Vainorius E, Mozaffari E, Hutcheson R.

Transpl Infect Dis. 2020 Apr 8:e13283. doi: 10.1111/tid.13283. [Epub ahead of print]

PMID:
32267590
2.

A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Stern A, Su Y, Lee YJ, Seo S, Shaffer B, Tamari R, Gyurkocza B, Barker J, Bogler Y, Giralt S, Perales MA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2020 Feb 20. pii: S1083-8791(20)30094-X. doi: 10.1016/j.bbmt.2020.02.009. [Epub ahead of print]

PMID:
32088367
3.

Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients.

Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, Lau C, Proli AJ, Papanicolaou GA, Seo SK, Barker JN, Perales MA, Giralt SA, Bhatt V.

Bone Marrow Transplant. 2020 Jan 14. doi: 10.1038/s41409-020-0785-9. [Epub ahead of print] No abstract available.

PMID:
31937928
4.

CMV Prevention and Treatment in Transplantation: What's New in 2019.

Stern A, Papanicolaou GA.

Curr Infect Dis Rep. 2019 Nov 15;21(11):45. doi: 10.1007/s11908-019-0699-0. Review.

PMID:
31732823
5.

False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy.

Hauser JR, Hong H, Babady NE, Papanicolaou GA, Tang YW.

J Clin Microbiol. 2019 Dec 23;58(1). pii: e01420-19. doi: 10.1128/JCM.01420-19. Print 2019 Dec 23.

PMID:
31694968
6.

Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.

Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, Lau C, Proli A, Barker J, Shaffer B, Giralt SA, Jakubowski AA, Papadopoulos EB, Papanicolaou GA, Seo SK, Perales MA.

Transpl Infect Dis. 2019 Dec;21(6):e13187. doi: 10.1111/tid.13187. Epub 2019 Oct 21.

PMID:
31585500
7.

Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.

Papanicolaou GA, Ustun C, Young JH, Chen M, Kim S, Woo Ahn K, Komanduri K, Lindemans C, Auletta JJ, Riches ML; CIBMTR® Infection and Immune Reconstitution Working Committee .

Clin Infect Dis. 2019 Oct 30;69(10):1771-1779. doi: 10.1093/cid/ciz031.

8.

Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.

Ustun C, Young JH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M.

Bone Marrow Transplant. 2019 Aug;54(8):1254-1265. doi: 10.1038/s41409-018-0401-4. Epub 2018 Dec 13.

9.

Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.

Huang YT, Su Y, Kim SJ, Nichols P, Burack D, Maloy M, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2019 Apr;25(4):791-799. doi: 10.1016/j.bbmt.2018.11.012. Epub 2018 Nov 24.

10.

Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.

Kamboj M, Cohen N, Huang YT, Kerpelev M, Jakubowski A, Sepkowitz KA, Papanicolaou GA, Seo SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):594-598. doi: 10.1016/j.bbmt.2018.11.008. Epub 2018 Nov 15.

11.

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.

Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S.

Clin Infect Dis. 2019 Apr 8;68(8):1255-1264. doi: 10.1093/cid/ciy706.

12.

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.

Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA, Nichols WG, Boeckh MJ; SUPPRESS Trial Clinical Study Group.

Biol Blood Marrow Transplant. 2019 Feb;25(2):369-381. doi: 10.1016/j.bbmt.2018.09.038. Epub 2018 Oct 4.

13.

Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.

Lee YJ, Neofytos D, Kim SJ, Cheteyan L, Huang YT, Papadopoulos EB, Jakubowski AA, Papanicolaou GA.

Transpl Infect Dis. 2018 Dec;20(6):e12977. doi: 10.1111/tid.12977. Epub 2018 Sep 3.

14.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.

Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A; V212 Protocol 001 Trial Team.

Lancet. 2018 May 26;391(10135):2116-2127. doi: 10.1016/S0140-6736(18)30631-7. Epub 2018 May 24.

PMID:
29856344
15.

Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA.

J Infect. 2018 Sep;77(3):227-234. doi: 10.1016/j.jinf.2018.03.015. Epub 2018 May 7.

16.

Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.

Rosillo C, Avila AM, Huang YT, Devlin S, Cho C, Montoro J, Maloy MA, Papanicolaou GA, Barba P, Perales MA.

Transpl Infect Dis. 2018 Aug;20(4):e12897. doi: 10.1111/tid.12897. Epub 2018 May 7.

17.

Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.

Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, Jakubowski AA, Papanicolaou GA.

Transpl Infect Dis. 2018 Jun;20(3):e12881. doi: 10.1111/tid.12881. Epub 2018 Apr 10.

18.

Paradoxical immune reconstitution inflammatory syndrome associated with disseminated tuberculosis infection in an unrelated donor cord blood transplant recipient.

Lee YJ, Bacchus M, Schmidt E, Chawla M, Barker JN, Papanicolaou GA.

Transpl Infect Dis. 2018 Jun;20(3):e12889. doi: 10.1111/tid.12889. Epub 2018 Apr 3.

19.

Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Epstein DJ, Seo SK, Brown JM, Papanicolaou GA.

J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i60-i72. doi: 10.1093/jac/dkx450. Review.

PMID:
29304213
20.

Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation.

Huang YT, Kim SJ, Lee YJ, Burack D, Nichols P, Maloy M, Perales MA, Giralt SA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1759-1766. doi: 10.1016/j.bbmt.2017.06.008. Epub 2017 Jun 28.

21.

Approach to adenovirus infections in the setting of hematopoietic cell transplantation.

Lee YJ, Prockop SE, Papanicolaou GA.

Curr Opin Infect Dis. 2017 Aug;30(4):377-387. doi: 10.1097/QCO.0000000000000379.

PMID:
28661410
22.

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis.

Dandoy CE, Ardura MI, Papanicolaou GA, Auletta JJ.

Bone Marrow Transplant. 2017 Aug;52(8):1091-1106. doi: 10.1038/bmt.2017.14. Epub 2017 Mar 27. Review.

PMID:
28346417
23.

Detection of human norovirus in intestinal biopsies from immunocompromised transplant patients.

Karandikar UC, Crawford SE, Ajami NJ, Murakami K, Kou B, Ettayebi K, Papanicolaou GA, Jongwutiwes U, Perales MA, Shia J, Mercer D, Finegold MJ, Vinjé J, Atmar RL, Estes MK.

J Gen Virol. 2016 Sep;97(9):2291-2300. doi: 10.1099/jgv.0.000545. Epub 2016 Jul 12.

24.

Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers.

Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, Pessin M, van Besien K, Perales MA, Giralt S, Sepkowitz K, Papanicolaou GA, Soave R, Kamboj M.

Clin Infect Dis. 2016 Aug 15;63(4):565-8. doi: 10.1093/cid/ciw330. Epub 2016 May 19.

25.

Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.

Huang YT, Neofytos D, Foldi J, Kim SJ, Maloy M, Chung D, Castro-Malaspina H, Giralt SA, Papadopoulos E, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1480-1486. doi: 10.1016/j.bbmt.2016.05.003. Epub 2016 May 10.

26.

Toxoplasma Encephalitis in Atypical Hosts at an Academic Cancer Center.

Morjaria S, Epstein DJ, Romero FA, Taur Y, Seo SK, Papanicolaou GA, Hatzoglou V, Rosenblum M, Perales MA, Scordo M, Kaltsas A.

Open Forum Infect Dis. 2016 Mar 30;3(2):ofw070. doi: 10.1093/ofid/ofw070. eCollection 2016 Mar.

27.

Lymphangitic papules caused by Nocardia takedensis.

Chung E, Pulitzer MP, Papadopoulos EB, Papanicolaou GA, Babady NE, Marchetti MA.

JAAD Case Rep. 2015 May 2;1(3):126-8. doi: 10.1016/j.jdcr.2015.03.001. eCollection 2015 May. No abstract available.

28.

Cutaneous involvement of disseminated adenovirus infection in an allogeneic stem cell transplant recipient.

Keyes A, Mathias M, Boulad F, Lee YJ, Marchetti MA, Scaradavou A, Spitzer B, Papanicolaou GA, Wieczorek I, Busam KJ.

Br J Dermatol. 2016 Apr;174(4):885-888. doi: 10.1111/bjd.14369. Epub 2016 Feb 18.

29.

Screening and Prevention of Hepatitis B Virus Reactivation During Chemotherapy.

Ludwig E, Cohen N, Papanicolaou GA, Seo SK.

Oncology (Williston Park). 2015 Dec;29(12):937, 940, 943. Review. No abstract available.

30.

Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.

Lee YJ, Huang YT, Kim SJ, Maloy M, Tamari R, Giralt SA, Papadopoulos EB, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2016 Jan;22(1):174-8. doi: 10.1016/j.bbmt.2015.08.019. Epub 2015 Aug 28.

31.

Brincidofovir for polyomavirus-associated nephropathy after allogeneic hematopoietic stem cell transplantation.

Papanicolaou GA, Lee YJ, Young JW, Seshan SV, Boruchov AM, Chittick G, Momméja-Marin H, Glezerman IG.

Am J Kidney Dis. 2015 May;65(5):780-4. doi: 10.1053/j.ajkd.2014.11.020. Epub 2015 Jan 17.

32.

Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.

Ann Intern Med. 2015 Jan 6;162(1):1-10. doi: 10.7326/M13-2729.

33.

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, El Idrissi M, Heineman TC, Berkowitz EM.

Blood. 2014 Nov 6;124(19):2921-9. doi: 10.1182/blood-2014-04-573048. Epub 2014 Sep 18.

34.

Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.

Seo SK, Xiao K, Huang YT, Jongwutiwes U, Chung D, Maloy M, Giralt S, Barker JN, Jakubowski AA, Papanicolaou GA.

J Infect. 2014 Oct;69(4):341-351. doi: 10.1016/j.jinf.2014.06.004. Epub 2014 Jun 12.

35.

Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantations.

Lee YJ, Zheng J, Kolitsopoulos Y, Chung D, Amigues I, Son T, Choo K, Hester J, Giralt SA, Glezerman IG, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1204-10. doi: 10.1016/j.bbmt.2014.04.017. Epub 2014 Apr 23.

36.

Severe influenza and S. aureus pneumonia: for whom the bell tolls?

Papanicolaou GA.

Virulence. 2013 Nov 15;4(8):666-8. doi: 10.4161/viru.26957. Epub 2013 Oct 28. No abstract available.

37.

Disseminated adenovirus infection in cancer patients presenting with focal pulmonary consolidation.

Lee YJ, Palomino-Guilen P, Babady NE, Lamson DM, St George K, Tang YW, Papanicolaou GA.

J Clin Microbiol. 2014 Jan;52(1):350-3. doi: 10.1128/JCM.01893-13. Epub 2013 Oct 16.

38.

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group.

N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.

39.

Effect of linezolid on clinical severity and pulmonary cytokines in a murine model of influenza A and Staphylococcus aureus coinfection.

Liu X, He Y, Xiao K, White JR, Fusco DN, Papanicolaou GA.

PLoS One. 2013;8(3):e57483. doi: 10.1371/journal.pone.0057483. Epub 2013 Mar 5.

40.

Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Lee YJ, Chung D, Xiao K, Papadopoulos EB, Barker JN, Small TN, Giralt SA, Zheng J, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2013 Mar;19(3):387-92. doi: 10.1016/j.bbmt.2012.10.014. Epub 2012 Oct 22.

41.

Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient.

Jacobs S, George A, Papanicolaou GA, Lacouture ME, Tan BH, Jakubowski AA, Kaltsas A.

Transpl Infect Dis. 2012 Aug;14(4):410-4. doi: 10.1111/j.1399-3062.2011.00681.x. Epub 2011 Sep 8.

PMID:
22093773
42.

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.

Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M; Maribavir 1263-300 Clinical Study Group.

Lancet Infect Dis. 2011 Apr;11(4):284-92. doi: 10.1016/S1473-3099(11)70024-X. Epub 2011 Mar 21. Erratum in: Lancet Infect Dis. 2011 May;11(5):343.

PMID:
21414843
43.

Echinacea purpurea aerial extract alters course of influenza infection in mice.

Fusco D, Liu X, Savage C, Taur Y, Xiao W, Kennelly E, Yuan J, Cassileth B, Salvatore M, Papanicolaou GA.

Vaccine. 2010 May 21;28(23):3956-62. doi: 10.1016/j.vaccine.2010.03.047. Epub 2010 Apr 9.

44.

Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.

Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A, Barker J, Papanicolaou GA.

Biol Blood Marrow Transplant. 2010 Jan;16(1):46-52. doi: 10.1016/j.bbmt.2009.08.015. Epub 2009 Oct 9.

45.

Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation.

Cohen N, Mihu CN, Seo SK, Chung D, Chou J, Heller G, Papanicolaou GA.

Biol Blood Marrow Transplant. 2009 Oct;15(10):1337-41. doi: 10.1016/j.bbmt.2009.05.021. Epub 2009 Jul 26.

46.

Toll-like receptor 4 polymorphisms and risk of gram-negative bacteremia after allogeneic stem cell transplantation. A prospective pilot study.

Mensah NY, Peterlongo P, Steinherz P, Pamer EG, Satagopan J, Papanicolaou GA.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1130-3. doi: 10.1016/j.bbmt.2009.04.012. Epub 2009 Jun 26. Erratum in: Biol Blood Marrow Transplant. 2010 Jan;16(1):128. Yaa, Mensah Nana [corrected to Mensah, Nana Yaa]; Paolo, Peterlongo [corrected to Peterlongo, Paolo]; Peter, Steinherz [corrected to Steinherz, Peter]; Eric, Pamer G [corrected to Pamer, Eric G]; Jaya, Satagopan [corrected to Satagopan, Jaya].

47.

Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study.

Mihu CN, Schaub J, Kesh S, Jakubowski A, Sepkowitz K, Pamer EG, Papanicolaou GA.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1429-33. doi: 10.1016/j.bbmt.2008.09.005.

48.

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.

Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, Alangaden GJ, Chemaly RF, Petersen F, Chao N, Klein J, Sprague K, Villano SA, Boeckh M.

Blood. 2008 Jun 1;111(11):5403-10. doi: 10.1182/blood-2007-11-121558. Epub 2008 Feb 19.

49.
50.

Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation.

Mihu CN, King E, Yossepovitch O, Taur Y, Jakubowski A, Pamer E, Papanicolaou GA.

Transpl Infect Dis. 2008 Jun;10(3):162-7. Epub 2007 Jul 27.

PMID:
17662036

Supplemental Content

Loading ...
Support Center